oxonic acid has been researched along with Cancer of Gastrointestinal Tract in 16 studies
Oxonic Acid: Antagonist of urate oxidase.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nutritional therapy is used to reduce the adverse events (AEs) of anticancer drugs." | 2.82 | Oral administration of the amino acids cystine and theanine attenuates the adverse events of S-1 adjuvant chemotherapy in gastrointestinal cancer patients. ( Hashimoto, T; Honda, H; Kakita, T; Kayahara, T; Kurihara, S; Oikawa, M; Oishi, H; Oyama, A; Shibakusa, T; Tochikubo, K; Tsuchiya, T, 2016) |
| "In a 14-day dosing schedule, the MTD of S-1 was 30 mg/m2 and preliminary evidence of antitumor activity was seen in a North American population with refractory upper gastrointestinal malignancies." | 2.73 | Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer. ( Anbe, H; Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Houghton, M; Kulke, MH; Meyerhardt, JA; Regan, E; Ryan, DP; Urrea, P; Zhang, J; Zhu, AX, 2007) |
| "Therapy for patients with advanced gastric cancer is not satisfactory." | 2.43 | Rapid development of S-1 in the west for therapy of advanced gastric carcinoma. ( Ajani, JA, 2006) |
| " The prothrombin time international normalized ratio divided by current warfarin dosage (PT-INR/dose) was measured over time to evaluate warfarin titer in each patient." | 1.43 | Impact of capecitabine and S-1 on anticoagulant activity of warfarin in patients with gastrointestinal cancer. ( Doki, Y; Haraguchi, N; Hata, T; Kudo, T; Mizushima, T; Mori, M; Nishimura, J; Sakai, D; Satoh, T; Takahashi, H; Yamamoto, H, 2016) |
| "To report canalicular stenosis as a side effect of the new antineoplastic agent S-1." | 1.33 | Canalicular and nasolacrimal duct blockage: an ocular side effect associated with the antineoplastic drug S-1. ( Ajani, J; Esmaeli, B; Golio, D; Lubecki, L, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (18.75) | 18.2507 |
| 2000's | 7 (43.75) | 29.6817 |
| 2010's | 5 (31.25) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Luo, D | 1 |
| Wang, L | 1 |
| Chen, X | 1 |
| Xiong, Y | 1 |
| Yi, F | 1 |
| Ding, J | 1 |
| Ding, H | 1 |
| Wei, Y | 1 |
| Zhang, W | 1 |
| Zhang, X | 2 |
| Cao, C | 2 |
| Zhang, Q | 1 |
| Chen, Y | 1 |
| Gu, D | 2 |
| Shen, Y | 1 |
| Gong, Y | 1 |
| Chen, J | 2 |
| Tang, C | 2 |
| Kuang, M | 1 |
| He, M | 1 |
| Tsuchiya, T | 1 |
| Honda, H | 1 |
| Oikawa, M | 1 |
| Kakita, T | 1 |
| Oyama, A | 1 |
| Oishi, H | 1 |
| Tochikubo, K | 1 |
| Hashimoto, T | 1 |
| Kurihara, S | 1 |
| Shibakusa, T | 1 |
| Kayahara, T | 1 |
| Hata, T | 2 |
| Kudo, T | 1 |
| Sakai, D | 1 |
| Takahashi, H | 1 |
| Haraguchi, N | 1 |
| Nishimura, J | 1 |
| Mizushima, T | 1 |
| Yamamoto, H | 1 |
| Doki, Y | 1 |
| Mori, M | 1 |
| Satoh, T | 2 |
| Sakata, Y | 2 |
| Hoff, PM | 1 |
| Saad, ED | 1 |
| Ajani, JA | 2 |
| Lassere, Y | 1 |
| Wenske, C | 1 |
| Medgyesy, D | 1 |
| Dwivedy, S | 1 |
| Russo, M | 1 |
| Pazdur, R | 1 |
| Yamada, Y | 1 |
| Hamaguchi, T | 1 |
| Goto, M | 1 |
| Muro, K | 1 |
| Matsumura, Y | 1 |
| Shimada, Y | 2 |
| Shirao, K | 1 |
| Nagayama, S | 1 |
| Schöffski, P | 1 |
| Esmaeli, B | 1 |
| Golio, D | 1 |
| Lubecki, L | 1 |
| Ajani, J | 1 |
| Zhu, AX | 1 |
| Clark, JW | 1 |
| Ryan, DP | 1 |
| Meyerhardt, JA | 1 |
| Enzinger, PC | 1 |
| Earle, CC | 1 |
| Fuchs, CS | 1 |
| Regan, E | 1 |
| Anbe, H | 1 |
| Houghton, M | 1 |
| Zhang, J | 1 |
| Urrea, P | 1 |
| Kulke, MH | 1 |
| Taguchi, T | 3 |
| Shirasaka, T | 1 |
| Aiba, K | 1 |
| Araki, H | 1 |
| Suzuki, M | 1 |
| Terashima, M | 1 |
| Mikami, Y | 1 |
| Sugimachi, K | 1 |
| Maehara, Y | 1 |
| Horikoshi, N | 1 |
| Mitachi, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Trial of Cisplatin Combined With Oral TS-1 in Patients With Advanced Solid Tumors With Different Degrees of Liver Dysfunction[NCT03519074] | Phase 2 | 48 participants (Anticipated) | Interventional | 2016-07-22 | Recruiting | ||
| A Phase I, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors[NCT02454062] | Phase 1 | 120 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| A Phase I Study of S-1 in Combination With Radiotherapy in Locally Advanced or Recurrent Gastric Cancer[NCT01291407] | Phase 1 | 27 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for oxonic acid and Cancer of Gastrointestinal Tract
| Article | Year |
|---|---|
Comparison of Platinum/S-1 and Platinum/5-Fluorouracil as First-Line Chemotherapy for Advanced Gastric or Gastroesophageal Junction Cancer: A Meta-Analysis Based on Randomized Controlled Trials.
Topics: Antineoplastic Agents; Coordination Complexes; Disease-Free Survival; Drug Combinations; Drug Therap | 2020 |
Comparison of the efficacy and safety of S-1-based and capecitabine-based regimens in gastrointestinal cancer: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Combinations; Fluo | 2014 |
Survival benefit from S-1 as compared to Fluorouracil in Asian patients with advanced gastrointestinal cancer: a meta-analysis.
Topics: Antineoplastic Agents; Asian People; Drug Combinations; Fluorouracil; Gastrointestinal Neoplasms; Hu | 2014 |
S-1 for the treatment of gastrointestinal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothec | 2012 |
The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as To | 2004 |
Rapid development of S-1 in the west for therapy of advanced gastric carcinoma.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2006 |
[Gastrointestinal cancer and oral anticancer agents].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Camptothecin; Drug Com | 1999 |
[Combination therapy of continuous venous infusion (CVI) of 5-FU and low dose consecutive cisplatin (CDDP), and the new oral anti-cancer drug S-1 for advanced gastro-intestinal cancer].
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Cyc | 1999 |
4 trials available for oxonic acid and Cancer of Gastrointestinal Tract
| Article | Year |
|---|---|
Oral administration of the amino acids cystine and theanine attenuates the adverse events of S-1 adjuvant chemotherapy in gastrointestinal cancer patients.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Cystine; | 2016 |
Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Dose-Response Relationship, Drug; Dr | 2003 |
Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Comb | 2007 |
An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Drug Combinations; Fluorouracil; Gastrointestinal Neop | 1999 |
4 other studies available for oxonic acid and Cancer of Gastrointestinal Tract
| Article | Year |
|---|---|
Impact of capecitabine and S-1 on anticoagulant activity of warfarin in patients with gastrointestinal cancer.
Topics: Anticoagulants; Antimetabolites, Antineoplastic; Capecitabine; Drug Combinations; Drug Interactions; | 2016 |
Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 2003 |
Canalicular and nasolacrimal duct blockage: an ocular side effect associated with the antineoplastic drug S-1.
Topics: Aged; Antimetabolites, Antineoplastic; Dacryocystorhinostomy; Drug Combinations; Female; Gastrointes | 2005 |
Recent development of anti-cancer drugs for treatment of GI malignancies in Japan.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothe | 2002 |